BioMérieux to fork over $450M for Utah Dx outfit

French diagnostics developer bioMerieux is ponying up $450 million for the newly renamed BioFire Diagnostics, a move that helps consolidate its position in infectious disease testing with one strategic move. What's more, bioMérieux chairman and CEO Jen-Luc Belingard envisions using BioFire's Salt Lake City, UT, headquarters and its 500-plus employees as a base from which to build a greater presence in molecular diagnostics down the line. (bioMérieux has been better known globally for in vitro diagnostics.) Story

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.